BIT Capital GmbH raised its holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 239.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 285,954 shares of the company's stock after buying an additional 201,808 shares during the quarter. BIT Capital GmbH owned approximately 0.36% of Viridian Therapeutics worth $5,482,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently modified their holdings of the company. R Squared Ltd purchased a new stake in Viridian Therapeutics in the fourth quarter valued at approximately $26,000. AlphaQuest LLC grew its stake in shares of Viridian Therapeutics by 119.0% during the 4th quarter. AlphaQuest LLC now owns 2,795 shares of the company's stock valued at $54,000 after buying an additional 1,519 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Viridian Therapeutics by 17.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,997 shares of the company's stock worth $318,000 after buying an additional 2,036 shares during the last quarter. Arizona State Retirement System raised its position in shares of Viridian Therapeutics by 19.5% in the 4th quarter. Arizona State Retirement System now owns 16,596 shares of the company's stock worth $318,000 after buying an additional 2,708 shares during the period. Finally, Corebridge Financial Inc. boosted its holdings in Viridian Therapeutics by 8.6% in the fourth quarter. Corebridge Financial Inc. now owns 36,336 shares of the company's stock valued at $697,000 after acquiring an additional 2,878 shares during the last quarter.
Analyst Upgrades and Downgrades
A number of equities analysts have recently commented on the company. Royal Bank of Canada raised their price objective on Viridian Therapeutics from $44.00 to $47.00 and gave the stock an "outperform" rating in a report on Tuesday, December 17th. Needham & Company LLC reaffirmed a "buy" rating and set a $38.00 price target on shares of Viridian Therapeutics in a research report on Tuesday, January 7th. HC Wainwright reissued a "buy" rating and issued a $34.00 price objective on shares of Viridian Therapeutics in a research report on Monday, December 16th. Finally, Wells Fargo & Company restated an "equal weight" rating and set a $27.00 target price (down previously from $37.00) on shares of Viridian Therapeutics in a report on Thursday, December 19th. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $35.70.
Check Out Our Latest Stock Report on VRDN
Viridian Therapeutics Stock Performance
Shares of VRDN stock traded down $0.94 during trading hours on Monday, reaching $13.50. The stock had a trading volume of 286,259 shares, compared to its average volume of 1,168,753. The firm has a market capitalization of $1.10 billion, a PE ratio of -3.14 and a beta of 1.05. The firm has a 50-day simple moving average of $16.75 and a 200-day simple moving average of $19.71. Viridian Therapeutics, Inc. has a twelve month low of $11.40 and a twelve month high of $27.20. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.55 and a quick ratio of 18.55.
Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.81) earnings per share for the quarter, beating analysts' consensus estimates of ($1.05) by $0.24. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The company had revenue of $0.07 million for the quarter, compared to analysts' expectations of $0.05 million. As a group, equities analysts forecast that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current year.
Viridian Therapeutics Company Profile
(
Free Report)
Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.
See Also
Before you consider Viridian Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viridian Therapeutics wasn't on the list.
While Viridian Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
